Hypoxia-inducible factor 1-alpha is a transcription factor that responds to low oxygen availability, regulating expression of genes involved in glycolysis, angiogenesis, erythropoiesis, and cell survival. HIF-1α is the master regulator of the cellular hypoxia response.
Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylases (PHDs, requiring oxygen, 2-oxoglutarate, iron, ascorbate), marking it for ubiquitination by VHL and proteasomal degradation. In hypoxia, PHDs are inactive, HIF-1α accumulates, translocates to nucleus, dimerizes with HIF-1β (ARNT), and binds hypoxia response elements (HREs) on target genes. Induces VEGF (angiogenesis), EPO (erythropoiesis), GLUT1 (glucose uptake), glycolytic enzymes (metabolic shift to anaerobic), and survival factors. Also activated by inflammation (via NF-κB), ROS, and metabolic factors (succinate, fumarate).
HIF-1α drives pathological processes when chronically activated: cancer (Warburg metabolism, angiogenesis), endometriosis (lesion survival in hypoxic peritoneum), chronic inflammation (M1 macrophage polarization), and tissue fibrosis. Therapeutically, HIF-1α stabilization (via PHD inhibitors) treats anemia. However, in cancer/endometriosis, HIF-1α inhibitors are therapeutic targets. Context determines whether HIF-1α is beneficial (acute ischemia adaptation) or harmful (chronic activation in disease).
- Master regulator of cellular response to hypoxia
- Degraded under normoxia by PHD-VHL-ubiquitin pathway
- Stabilized in hypoxia, inflammation, or metabolic dysfunction
- Induces VEGF (angiogenesis), EPO (RBC production), glycolytic enzymes
- Promotes metabolic shift to glycolysis (Warburg effect)
- PHDs require oxygen, 2-oxoglutarate, iron, vitamin C
- Activated by ROS, succinate, fumarate, lactate (pseudo-hypoxia)
- Critical in cancer progression and metastasis
- PHD inhibitors (daprodustat, roxadustat) used to treat anemia
- 2-methoxyestradiol inhibits HIF-1α (potential endometriosis treatment)
- hypoxia — Primary trigger of HIF-1α stabilization and activation
- VEGF — HIF-1α master regulator inducing VEGF for angiogenesis
- angiogenesis — HIF-1α promotes new blood vessel formation via VEGF
- EPO — HIF-1α induces erythropoietin production increasing RBC mass
- glycolysis — HIF-1α upregulates glycolytic enzymes (Warburg metabolism)
- GLUT1 — HIF-1α induces glucose transporter increasing glucose uptake
- Warburg effect — HIF-1α drives aerobic glycolysis in cancer and inflammation
- inflammation — Inflammatory signals (NF-κB, IL-1β) stabilize HIF-1α independent of hypoxia
- NF-κB — Inflammation-induced NF-κB stabilizes HIF-1α
- macrophages — HIF-1α drives M1 polarization and glycolytic metabolism
- cancer — Constitutive HIF-1α activation promotes tumor growth, angiogenesis, metastasis
- endometriosis — HIF-1α supports endometriotic lesion survival in hypoxic environment
- PHD inhibitors — Stabilize HIF-1α therapeutically (e.g., for anemia in kidney disease)
- VHL — E3 ubiquitin ligase targeting hydroxylated HIF-1α for degradation
- 2-oxoglutarate — Substrate for PHD enzymes; TCA cycle intermediate
- iron — Required cofactor for PHD activity; deficiency pseudo-stabilizes HIF
- vitamin C — Required cofactor for PHD activity
- succinate — Accumulation inhibits PHDs, stabilizing HIF-1α (pseudo-hypoxia)
- ROS — Oxidative stress can stabilize HIF-1α independent of oxygen
- mitochondria — Mitochondrial dysfunction generates ROS and metabolites stabilizing HIF-1α